CompanyGraphWhat stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $1.93B, above the global median of $1.2B
- FinancialsAltman Z-Score 9.67: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
12.91BCNY1.93B · vs all stocks (USD)
Trailing P/E
538.65xRevenue (TTM)
901.08MCNY134.50M · vs all stocks (USD)
Profit Margin
2.65%Beta
-0.3550xvs all stocks
52-Week Change
89.47%vs all stocks
Market Capitalization
12.91BCNY1.93B · vs all stocks (USD)
Enterprise Value
11.59BCNY1.73B · vs all stocks (USD)
Trailing P/E
538.65xPrice to Sales (TTM)
14.33xPrice to Book (MRQ)
5.46xEnterprise to Revenue
12.86xEnterprise to EBITDA
139.87xGross Margin
32.23%Profit Margin
2.65%Operating Margin
5.35%Return on Assets (TTM)
0.29%Return on Equity (TTM)
1.07%Revenue (TTM)
901.08MCNY134.50M · vs all stocks (USD)
Revenue per Share (TTM)
6.45CNYUpdated Sep 22, 2026Quarterly Revenue Growth
53.50%Gross Profit (TTM)
194.86MCNY29.09M · vs all stocks (USD)
EBITDA (TTM)
125.96MCNY18.80M · vs all stocks (USD)
Net Income (TTM)
23.85MCNY3.56M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
53.51%Operating Cash Flow (TTM)
378.83MCNY56.55M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
208.00MCNY31.05M · vs all stocks (USD)
Payout Ratio
188.24%Minority Interest (Equity)
38.58MCNYFY2025 · Dec 31, 2025Revenue
811.33MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
600.73MCNYFY2025 · Dec 31, 2025Gross Profit
210.59MCNYFY2025 · Dec 31, 2025Operating Income
22.87MCNY3.41M · vs all stocks (USD)
Pre-tax Income
-16.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
-5.81MCNYFY2025 · Dec 31, 2025Net Income
-10.48MCNYFY2025 · Dec 31, 2025EBIT
-7.76MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
125.96MCNYFY2025 · Dec 31, 2025Research & Development
45.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
95.52MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.45MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.54MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
138.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
138.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-10.48MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-20.03MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-264.36MCNYFY2025 · Dec 31, 2025Free Cash Flow
-398.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.22BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-10.48MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.57MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-104.52MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-164.93MCNYFY2025 · Dec 31, 2025Capital Expenditures
-133.94MCNYFY2025 · Dec 31, 2025Purchase of Investments
-100.34MCNYFY2025 · Dec 31, 2025Sale of Investments
100.34MCNYFY2025 · Dec 31, 2025Other Investing Activity
11.84MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-122.10MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-500.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-45.12MCNYFY2025 · Dec 31, 2025Other Financing Charges
-16.54MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-62.16MCNYFY2025 · Dec 31, 2025Shares Outstanding
140.98MSharesUpdated Sep 22, 2026Float Shares
118.89MSharesUpdated Sep 22, 2026% Held by Insiders
63.08%vs all stocks
% Held by Institutions
18.56%vs all stocks
Total Cash (MRQ)
1.49BCNY222.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
10.59CNYUpdated Sep 22, 2026Total Debt (MRQ)
130.26MCNY19.44M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0541xCurrent Ratio (MRQ)
2.28xBook Value per Share (MRQ)
16.79CNYUpdated Sep 22, 2026Total Assets
3.25BCNY485.64M · vs all stocks (USD)
Total Current Assets
2.18BCNYFY2025 · Dec 31, 2025Total Liabilities
891.41MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.07BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
179.22MCNYFY2025 · Dec 31, 2025Total Current Liabilities
712.19MCNYFY2025 · Dec 31, 2025Cash
979.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
308.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.29BCNYFY2025 · Dec 31, 2025Accounts Receivable
218.23MCNYFY2025 · Dec 31, 2025Inventory
430.46MCNYFY2025 · Dec 31, 2025Accounts Payable
69.00MCNYFY2025 · Dec 31, 2025Short-term Debt
11.09MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.87MCNYFY2025 · Dec 31, 2025Long-term Debt
104.59MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.16MCNYFY2025 · Dec 31, 2025Common Stock (Book)
140.98MCNYFY2025 · Dec 31, 2025Retained Earnings
453.08MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.36BCNY352.58M · vs all stocks (USD)
52-Week Low
40.26CNYUpdated Sep 22, 202652-Week High
103.69CNYUpdated Sep 22, 202652-Week Change
89.47%vs all stocks
Beta
-0.3550xvs all stocks
50-Day MA
84.45CNYUpdated Sep 22, 2026200-Day MA
66.07CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.75MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.35MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.1700CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.54Receivables vs revenue divergence: 2.25
Financial Health
Altman Z-Score 9.67: safe zoneNotable
Altman Z-Score: 9.67
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $1.93B, above the global median of $1.2BNotable
Market cap (USD): 1,927,001,564.308Global Median: 1,201,862,193
Levered free cash flow is $31.05M, above the global median of $18.92MNotable
Levered free cash flow (USD): 31,047,503.212Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule